GSK Pays $34 Million Upfront To License Idenix’s Phase II HIV Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Idenix says deal will give it the ability to focus on trio of hepatitis C programs.
You may also be interested in...
Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In
The potential for combination therapy involving direct-acting antivirals in the growing hepatitis C space has garnered significant attention from industry firms big and small. At present, even though the standard of care - ribavirin plus one of two branded pegylated interferons (Roche's Pegasys and Schering-Plough's Pegintron) - is effective only in about half of all HCV patients, those drugs generate annual net sales of roughly $2.5 billion
Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In
The potential for combination therapy involving direct-acting antivirals in the growing hepatitis C space has garnered significant attention from industry firms big and small. At present, even though the standard of care - ribavirin plus one of two branded pegylated interferons (Roche's Pegasys and Schering-Plough's Pegintron) - is effective only in about half of all HCV patients, those drugs generate annual net sales of roughly $2.5 billion
Idenix Targets HIV Partner By Year End
IDX899 boasts positive Phase I/II prospects and potential as a fixed-dose combo.